About
Aidy builds a free mobile and text-based companion for people living with Crohn’s disease and ulcerative colitis. It helps users track diet, symptoms, and treatments, identify triggers and trends, learn about their condition, and share physician-friendly reports with care teams; its key differentiator is combining structured health tracking with personalized trend analysis and education.
Market
Aidy competes in digital health for inflammatory bowel disease management, positioning itself as a free, consumer-focused companion for people with Crohn’s disease and ulcerative colitis rather than as a replacement for clinical care. It differentiates through AI-assisted food photo/text logging, longitudinal analysis of diet and treatment adherence against symptoms, an IBD-specific chatbot, and doctor-ready reports; competitors span condition-management apps, evidence-based nutrition programs, medication-support services, and virtual GI-care platforms.
Aidy primarily serves individual consumers living with Crohn’s disease or ulcerative colitis, including patients managing biologic or other prescribed treatments who want to track symptoms, diet, adherence, and communicate more effectively with GI care teams. Its secondary commercial audience includes health plans, employers, and researchers that may sponsor or use the service.
At a Glance
Problem
Aidy addresses the day-to-day burden of inflammatory bowel disease, beginning with Crohn’s disease and ulcerative colitis. Patients often need to coordinate symptoms, diet, medications, treatment adherence, flare warning signs, and clinician communication, yet the relevant information is fragmented and difficult to interpret. The economic stakes are significant: direct IBD healthcare expenses, including visits, hospitalizations, and medications, average roughly $9,000–$12,000 per person annually. Aidy’s core use case is helping a patient identify relationships between food, treatment adherence, and symptoms early enough to avoid triggers, manage disease more proactively, and reduce the risk of acute escalation.
Product / Service
Aidy is a consumer digital-health companion delivered through a free SMS entry point and an iPhone app. Users record meals, symptoms, bowel movements, medications, and treatments; Aidy then uses clinical indices and pattern analysis to show disease trends and possible relationships between diet, adherence, and symptoms. The app also includes an IBD-focused chatbot with tailored, research-backed educational answers, personalized learning, treatment reminders, and physician-friendly reports that can be shared with a care team. It explicitly positions itself as educational and self-tracking support rather than a substitute for medical care.
The company says the service is free for users and plans to generate revenue through health plans, employers, and researchers, although the App Store listing also shows Aidy Premium in-app purchase prices, suggesting its monetization model may be evolving. The intended benefit is to make condition management easier between appointments while giving patients and clinicians a more current, structured view of disease activity.
Market
Aidy competes in consumer health services and digital health, specifically digital tools for chronic-condition and IBD management. Its closest visible comparables include My IBD Care, which combines IBD tracking, education, and behavior-change support; MyGut, which focuses on helping people understand and follow their IBD while improving communication; and Crohn’s Tracker, which supports meal, flare, bowel-movement, and food-symptom tracking. Aidy differentiates itself through the combination of treatment adherence, clinical severity indices, pattern analysis, AI-guided education, and clinician-ready reporting.
The company is a Y Combinator Winter 2024 startup listed as active, with two employees in San Francisco. Product traction is visible but still early: its App Store listing shows an overall 4.7 rating from 18 ratings, and the app is available for download. The evidence does not establish a reliable current revenue, customer, or user count, so Aidy should be characterized as an active early-stage product with initial user validation rather than as a company with publicly verified scale or as definitively pre-revenue.
Founders & Leadership
Funding History
Y Combinator
Recent News
Y Combinator's 2026 digital-health directory lists Aidy as a mobile app and describes it as backed by Y Combinator, angel investors, and venture capital firms.
Aidy updated its practical guide on gradually reintroducing fiber after a Crohn's flare. The article was first published on November 22, 2025, and was last updated July 8, 2026.
Aidy published a guide for people newly diagnosed with inflammatory bowel disease, directing readers to get started with its personalized support for Crohn's disease and ulcerative colitis.
Aidy's Learning Center highlighted practical articles covering symptoms, medications, flares, nutrition, and everyday disease management.
Aidy published a caregiver-focused guide for new Crohn's disease or ulcerative-colitis diagnoses, emphasizing education and collaboration with a physician.
Aidy published an article covering new Crohn's treatment research and developments as part of its educational support content.
Aidy launched on Product Hunt as an all-in-one app intended to help people with inflammatory bowel disease identify triggers, share data with doctors, and reduce emergency-room visits.
Aidy published an educational explainer on corticosteroids, including prednisone and budesonide, and their use to calm intestinal inflammation.
Aidy published an educational comparison of Tremfya and Omvoh for ulcerative colitis as part of its personalized IBD-support content.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
Aidy is free for users and does not charge paid subscriptions. It generates revenue through relationships with health plans, employers, and researchers.